Trial Profile

Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN).

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

25 Mar 2020 Status changed from active, no longer recruiting to discontinued.
29 Feb 2020 Primary endpoint (2 year Tumor Progression free survival) has not been met.
29 Feb 2020 Results presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com